Replay, a genome writing company reprogramming biology by writing and delivering big DNA headquartered in San Diego, USA, and London, UK, today announced its launch with $55 million in seed financing.
The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial.
Private equity interest in early-stage biotech companies comes despite what is often a decade-long wait for revenue as technologies are developed, noted the Financial Times. PE firms including EQT, Carlyle and Abingworth have all recently bought or taken stakes in early-stage venture capital firms specializing in life sciences, it added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze